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SP-0537   
Cancer burden, radiotherapy utilisation, and outcomes 
M. Barton1, M.L. Yap1 
1Ingham Institute for Applied Medical Research, University of 
NSW, Liverpool BC NSW, Australia  
This work is presented on behalf of the GTFRCC Working 
Group #1 Members 
Purpose/Objective: To estimate the number of cases of 
cancer that would benefit from radiotherapy (RT) by country, 
the survival and local control benefits of radiotherapy and to 
calculate projections of demand and benefit to 2035 for input 
to GTFRCC investment framework. 
Methods: The CCORE model of optimal utilisation of RT and 
Globocan data on cancer incidence and projections by 
country were used to calculate the number of cases with an 
indication for RT where RT was the treatment of choice. The 
estimate does not include non-melanomatous skin cancer or 
benign conditions. Survival and local control benefit were 
calculated by meta-analysis of available results for each 
radiotherapy indication for the 10 most common cancers that 
comprise 75% of the world cancer burden. Palliative benefit 
was not included.  
Results: In 2012 there were 14 million new cases of cancer in 
the world. 7 million (50%) would benefit from RT. More than 
half of the cases were in Low and Middle Income Countries. 
For the 10 most common cancers, 1.3 million cases would 
have a local control benefit and 0.5 million would have a 
survival benefit from RT if all patients were treated 
according to guidelines. By 2035, 12 million cases would have 
an indication for RT and the benefit for the 10 most common 
cancers would be local control for 2 million and improved 
survival for 0.8 million.  
Conclusion: In 2012 7 million cases of cancer require 
radiotherapy. This will increase to 12 million by 2035.  
SP-0538   
GTFRCC Working Group #2: Radiotherapy Core Components 
and Costs 
J. Van Dyk1 
1Western University, Physics and Engineering, London, 
Canada  
2on behalf of GTFRCC Working Group #2 Members, ,  
Purpose: To estimate the additional infrastructure required 
and the corresponding costs in terms of facilities, equipment 
and personnel to make up for the shortfall in current capacity 
and to provide uniform global access to radiation therapy by 
2035. 
Methods: An activities-based cost calculation model was 
implemented to generate: (1) an operating cost/fraction 
excluding building costs (Rate #1), and (2) a total 
cost/fraction including capital costs to establish 
new/increased capacity (Rate #2). For total cost estimations, 
the numbers of fractions needed were obtained from GTFRCC 
Work Group #1. For the rate determinations, a modified 
version of the IAEA cost calculator was used which included 
staffing level determinations based on an IAEA consultants’ 
group and confirmed with published data. Cost estimations 
were determined for four categories of gross national 
income. Input data included numbers of fractions required 
(from Work Group#1), typical components of a four-machine 
start-up department, 3-D conformal radiation therapy as the 
standard of care, and brachytherapy as needed. 
Commercially available, typical equipment costs were used. 
National salary information for professional staff and capital 
building costs were obtained through a Delphi questionnaire 
process along with confirmation from publicly available 
databases. To determine overall costs required for increasing 
capacity, existing resources were obtained from the IAEA 
DIRAC database along with information from additional 
independent sources. Sensitivity analysis was performed by 
controlled variations in the input parameters. Comparisons 
were also made to the published literature and the results of 
the ESTRO HERO project. The cost of training new 
professionals was also estimated. 
Results: The major cost drivers include capital costs of new 
facilities and equipment, and personnel salaries. The Delphi 
questionnaire results demonstrated a huge variation in 
salaries in different countries. As a result, the relative 
capital costs versus operating costs also had a large variation 
demonstrating a relative capital/operating ratio of about 70-
80%/20-30%  in high income countries compared to as much 
as the reverse in low income settings. Estimates for a 
particular operating model for Rate#1 and Rate#2 in low-to-
middle income settings are approximately US$50/fraction and 
US$300/fraction.  
Conclusion: The infrastructure and cost modeling provides a 
means of estimating the resources needed to advance 
radiation therapy capabilities in different settings around the 
world. One operating model indicates that, in low-to-middle 
income settings, about 2,000 new four-machine departments 
are required, corresponding to about 8,000 megavoltage 
machines along with 14,000, 8,300, and 35,000 radiation 
oncology, medical physics, and radiation therapy trainees, 
respectively.  
SP-0539   
GTFRCC Investment Framework: Health and Economic 
Benefits of Radiotherapy in Low- and Middle-Income 
Countries  
D. Rodin1, R. Atun2 
1Princess Margaret Cancer Centre, Department of Radiation 
Oncology, Toronto, Canada  
2Harvard T.H. Chan School of Public Health, Department of 
Global Health and Population, Boston, USA  
Purpose: Radiotherapy (RT) is often thought to be a complex 
and expensive modality to implement in settings with limited 
resources and multiple competing priorities. We aimed to 
estimate the potential health and economic benefits that can 
be accrued in low- and middle-income countries (LMIC) with 
an increase in RT capacity over a 20-year period from 2015 to 
2035. 
Methods: We developed a series of Markov decision-analytic 
models for 9 cancer sites (breast, cervix, colorectal, head 
and neck, haematologic, lung, esophagus, prostate, stomach) 
to simulate the total life years saved (LYs), incremental 
costs, and selected economic benefits accrued from scaling 
up RT capacity at 3 different rates of investment (gradual, 
rapid, aspirational). Capacity was estimated from RT demand 
data (from Working Group #1) and the IAEA Directory of 
Radiotherapy Services (DIRAC). Analyses were stratified by 
World Bank income group region and outcome measures were 
evaluated under scenarios of existing and expanded 
radiotherapy capacity, with results projected over 20 years. 
The total operational and infrastructure costs (from Working 
Group #2) associated with RT scale were compared with the 
projected economic gains, defined as improved labour 
productivity measured using gross domestic product (GDP). 
All future costs and health benefits were discounted at an 
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annual rate of 3% in the base case analysis. We conducted 
sensitivity analyses to investigate how variation in overall 
survival with and without RT, RT demand, projected GDP 
growth rates, and operational and infrastructure costs per 
fraction impacted projections. 
Results:  In the base case “rapid” investment scenario, a 
total of 24,383,261 discounted life years are gained by 2035 
through scaling up radiotherapy capacity. This represents 
4,131,981 LYs in upper-middle, 11,006,360 LYs in lower-
middle, and 9,245,240 LYs in low-income countries. This 
results in a total of 124,389,936,346 USD discounted net 
monetary benefits accrued through productivity gains. 
Different investment scenarios and costing packages impact 
the rate of return.  
Conclusion: The health and economic benefits from 
improving access to radiotherapy capacity are projected to 
be substantial. Despite the capital costs associated with 
implementing radiotherapy infrastructure, the adoption of a 
long-term perspective demonstrates that in addition to the 
large health gains generated, the economic gains of 
radiotherapy investment are likely to offset programmatic 
costs. Scaling up radiotherapy capacity may be considered a 
cost-saving intervention, which may warrant priority within 
the health budgets of LMIC.  
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SP-0540   
Modulation of tumour vasculature: effects on hypoxia and 
tumour regrowth 
J.H. Muschel1, J.H. Im1, E. Fokas1, C.J. Kelly1, A. Gordon-
Weeks1, S.Y. Lim1 
1University of Oxford, Oncology, Oxford, United Kingdom  
 
The structure and mechanics of tumour vasculature as well as 
oxygen consumption by the cancer determines the levels of 
tumour hypoxia.  Vascular structure is affected by 
remodeling that can be altered after agents inhibition of 
oncogenic signaling in the cancer cells. Inhibition of the RAS-
PI3K signalling  pathway leads to morphological changes 
resulting in increased perfusion and decreased vascular 
tortuosity. At the same time inhibition of the pathway also 
leads to decreased oxygen consumption. Together then the 
result of RAS-PI3K inhibition is decreased tumour hypoxia and 
increased tumour growth delay after radiation therapy.   
While decreased hypoxia during radiation therapy should 
increase efficacy, recurrence of tumours after therapy could 
be expected to require neoangiogenesis. Inhibition of 
angiogenesis using an antibody to notch ligand DLL4 led to 
superadditive reduction in tumour regrowth after radiation.  
However these studies cannot fully describe the events that 
might occur after fractionated radiation.  After fractionated 
radiation we find increased deposition of the potent 
angiogenic stimulator, FGF2 by recruited myeloid cells.  In 
another oncologic setting, liver metastasis, we can show that 
myeloid cells recruited to the liver colonies are induced to 
express FGF2 and that inhibition of FGF2 reduced the liver 
colony growth. These studies raise the possibility of FGF2 as 
a target for therapy in the setting of fractionated radiation 
therapy.  
   
 
SP-0541   
The PI3K/mTOR pathway regulates oxygen metabolism via 
pyruvate dehydrogenase (PDH)-E1a phosphorylation 
A. Maity1, G.J. Cerniglia1, S. Dey1, S.M. Gallagher-Colombo1, 
N. Daurio1, S. Tuttle1, T.M. Busch1, R. Sun2, N. Denko2, A. 
Lin1, C. Koumenis1 
1Perelman School of Medicine of U. of Pennsylvania, 
Department of Radiation Oncology, Philadelphia PA, USA  
2Ohio State University School of Medicine, Department of 
Radiation Oncology, Columbus OH, USA  
 
Purpose: Inhibition of the PI3K/mTOR pathway decreases 
hypoxia within SQ20B human head and neck cancer 
xenografts. We set out to understand the molecular 
mechanism underlying this observation. 
Experimental Design:  We measured oxygen consumption 
using both a Clark electrode and an extracellular flux 
analyzer. We made these measurements after various 
pharmacologic and genetic manipulations.   
Results: Pharmacologic inhibition of the PI3K/mTOR pathway 
or genetic inhibition of Akt/PI3K decreased the oxygen 
consumption rate (OCR) in vitro in SQ20B and other cell lines 
by 30-40%.  Pharmacologic inhibition of this pathway 
increased phosphorylation of the E1a subunit of the pyruvate 
dehydrogenase (PDH) complex on Ser293, which inhibits 
activity of this critical gatekeeper of mitochondrial 
respiration. Expressing wild type PTEN in a doxycycline-
inducible manner in a cell line with mutant PTEN led to an 
increase in PDH-E1a phosphorylation and a decrease in OCR. 
Pre-treatment of SQ20B cells with dichloroacetate (DCA), 
which inhibits PDH-E1a phosphorylation by inhibiting 
dehydrogenase kinases (PDKs), reversed the decrease in OCR 
in response to PI3K/Akt/mTOR inhibition. Likewise, 
introduction of exogenous PDH-E1a that contains serine to 
alanine mutations, which can no longer be regulated by 
phosphorylation, also blunted the decrease in OCR seen with 
PI3K/mTOR inhibition.  
Conclusions: Our findings highlight an association between 
the PI3K/mTOR pathway and tumor cell oxygen consumption 
that is regulated in part by PDH phosphorylation.  These 
results have important implications for understanding the 
effects PI3K pathway activation in tumor metabolism and also 
in designing cancer therapy trials that use inhibitors of this 
pathway.   
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Biguanides and cancer: microenvironmental and anti-
proliferative effects at in vivo achievable concentrations 
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J. Frøkiær3, M.R. Horsman1, M. Busk1 
1Aarhus University Hospital, Department of Experimental 
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4Aarhus University Hospital, Biochemical Pathology, Aarhus 
C, Denmark  
 
Purpose/Objective: The anti-diabetic biguanides metformin 
(MET) and phenformin (PHEN) works by partial inhibition of 
respiration, and may have antineoplastic effects. Inhibition 
of respiration induces energetic stress and activation of the 
AMPK stress-signaling pathway possibly causing reduced 
tumor growth or cell death. Inhibition of respiration may also 
improve tumor oxygenation and thus radiosensitize tumors. 
Unfortunately, nearly all studies demonstrating anticancer 
effects of biguanides have used supraphysiological drug 
concentrations in vitro and ignored that cellular uptake 
depends on organic cation transporters (OCTs). The purpose 
of this study is to provide evidence for or against directly 
